Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 215

1.

Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy.

Porter BE, Jacobson C.

Epilepsy Behav. 2013 Dec;29(3):574-7. doi: 10.1016/j.yebeh.2013.08.037.

2.

Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome.

Hussain SA, Zhou R, Jacobson C, Weng J, Cheng E, Lay J, Hung P, Lerner JT, Sankar R.

Epilepsy Behav. 2015 Jun;47:138-41. doi: 10.1016/j.yebeh.2015.04.009. Epub 2015 Apr 29.

PMID:
25935511
3.

Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.

Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, Miller I, Flamini R, Wilfong A, Filloux F, Wong M, Tilton N, Bruno P, Bluvstein J, Hedlund J, Kamens R, Maclean J, Nangia S, Singhal NS, Wilson CA, Patel A, Cilio MR.

Lancet Neurol. 2016 Mar;15(3):270-8. doi: 10.1016/S1474-4422(15)00379-8. Epub 2015 Dec 24. Erratum in: Lancet Neurol. 2016 Apr;15(4):352.

PMID:
26724101
4.

Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy.

Press CA, Knupp KG, Chapman KE.

Epilepsy Behav. 2015 Apr;45:49-52. doi: 10.1016/j.yebeh.2015.02.043. Epub 2015 Apr 3.

PMID:
25845492
5.

Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.

Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, Katz R, Di Marzo V, Jutras-Aswad D, Notcutt WG, Martinez-Orgado J, Robson PJ, Rohrback BG, Thiele E, Whalley B, Friedman D.

Epilepsia. 2014 Jun;55(6):791-802. doi: 10.1111/epi.12631. Epub 2014 May 22. Review.

6.

Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.

Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, Scheffer IE, Thiele EA, Wright S; Cannabidiol in Dravet Syndrome Study Group.

N Engl J Med. 2017 May 25;376(21):2011-2020. doi: 10.1056/NEJMoa1611618.

7.

CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience.

Tzadok M, Uliel-Siboni S, Linder I, Kramer U, Epstein O, Menascu S, Nissenkorn A, Yosef OB, Hyman E, Granot D, Dor M, Lerman-Sagie T, Ben-Zeev B.

Seizure. 2016 Feb;35:41-4. doi: 10.1016/j.seizure.2016.01.004. Epub 2016 Jan 6.

8.

Cannabinoids in treatment-resistant epilepsy: A review.

O'Connell BK, Gloss D, Devinsky O.

Epilepsy Behav. 2017 May;70(Pt B):341-348. doi: 10.1016/j.yebeh.2016.11.012. Epub 2017 Feb 8. Review.

PMID:
28188044
9.

Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US.

Sands TT, Rahdari S, Oldham MS, Caminha Nunes E, Tilton N, Cilio MR.

CNS Drugs. 2018 Nov 20. doi: 10.1007/s40263-018-0589-2. [Epub ahead of print]

PMID:
30460546
10.

The case for medical marijuana in epilepsy.

Maa E, Figi P.

Epilepsia. 2014 Jun;55(6):783-6. doi: 10.1111/epi.12610. Epub 2014 May 22.

11.

Efficacy and safety of cannabis for treating children with refractory epilepsy.

Neale M.

Nurs Child Young People. 2017 Sep 11;29(7):32-37. doi: 10.7748/ncyp.2017.e907. Review.

PMID:
29115760
12.

From Cannabis to Cannabidiol to Treat Epilepsy, Where Are We?

Lippiello P, Balestrini S, Leo A, Coppola A, Citraro R, Elia M, Russo E, De Sarro G.

Curr Pharm Des. 2016;22(42):6426-6433. doi: 10.2174/1381612822666160831122722. Review.

PMID:
27587196
13.

Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex.

Hess EJ, Moody KA, Geffrey AL, Pollack SF, Skirvin LA, Bruno PL, Paolini JL, Thiele EA.

Epilepsia. 2016 Oct;57(10):1617-1624. doi: 10.1111/epi.13499. Epub 2016 Oct 3.

14.

Duration of use of oral cannabis extract in a cohort of pediatric epilepsy patients.

Treat L, Chapman KE, Colborn KL, Knupp KG.

Epilepsia. 2017 Jan;58(1):123-127. doi: 10.1111/epi.13617. Epub 2016 Nov 18.

15.

The case for assessing cannabidiol in epilepsy.

Cilio MR, Thiele EA, Devinsky O.

Epilepsia. 2014 Jun;55(6):787-90. doi: 10.1111/epi.12635. Epub 2014 May 22.

16.

Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy.

Geffrey AL, Pollack SF, Bruno PL, Thiele EA.

Epilepsia. 2015 Aug;56(8):1246-51. doi: 10.1111/epi.13060. Epub 2015 Jun 26.

17.

The protocol for the Cannabidiol in children with refractory epileptic encephalopathy (CARE-E) study: a phase 1 dosage escalation study.

Reithmeier D, Tang-Wai R, Seifert B, Lyon AW, Alcorn J, Acton B, Corley S, Prosser-Loose E, Mousseau DD, Lim HJ, Tellez-Zenteno J, Huh L, Leung E, Carmant L, Huntsman RJ.

BMC Pediatr. 2018 Jul 7;18(1):221. doi: 10.1186/s12887-018-1191-y.

18.

Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures.

Trevathan E, Kerls SP, Hammer AE, Vuong A, Messenheimer JA.

Pediatrics. 2006 Aug;118(2):e371-8. Epub 2006 Jul 17.

PMID:
16847080
19.

An Australian nationwide survey on medicinal cannabis use for epilepsy: History of antiepileptic drug treatment predicts medicinal cannabis use.

Suraev AS, Todd L, Bowen MT, Allsop DJ, McGregor IS, Ireland C, Lintzeris N.

Epilepsy Behav. 2017 May;70(Pt B):334-340. doi: 10.1016/j.yebeh.2017.02.005. Epub 2017 Feb 24.

20.

Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.

Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM; GWPCARE3 Study Group.

N Engl J Med. 2018 May 17;378(20):1888-1897. doi: 10.1056/NEJMoa1714631.

Supplemental Content

Support Center